Expand all sections

Masitinib

Masican

Extended indication GIST
Therapeutic value No judgement

Product

Active substance Masitinib
Domain Oncology and Hematology
Main indication Stomach cancer
Extended indication GIST
Proprietary name Masican
Manufacturer AB Science
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Orphan drug No
Additional remarks Wordt onderzocht in veel verschillende indicaties. Eerst in mastocytosis, AML, etc. Negatieve CHMP-opinie voor mastocytosis en AML in september 2017.

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

Patient volume

0 - 306

Market share is generally not included unless otherwise stated.
References NKR
Additional remarks NKR 2016: 306 gastrointestinale sarcomen en stromatumoren.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions Er lopen meerdere PhIII studies.

Other information

There is currently no futher information available.